Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Povidone→

Povidone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9003-39-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Polyvinylpyrrolidone (PVP)pharmaceutical polymer excipient and carrier
Mechanism of action
A water-soluble polymer used as a binder, solubiliser, film-former and stabilising excipient. Povidone itself does not have a single systemic therapeutic mechanism; antimicrobial activity in povidone-iodine formulations is attributable to available iodine, not the polymer alone.
Indications / reported uses
  • Used as a pharmaceutical excipient in tablets, capsules, topical and other dosage forms; do not assign povidone-iodine antiseptic indications to povidone alone

Sources: USP–NF — Povidone monograph · PubChem — Polyvinylpyrrolidone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Povidone Environmental Risk Assessment (ERA) (the Povidone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.